Press Releases

26 Jun 2024 PR Newswire Positive Xanamem® biomarker trial published in the Journal of Alzheimer’s Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
22 Apr 2024 PR Newswire Enrolment completed in Actinogen’s XanaCIDD phase 2a cognition & depression trial
15 Apr 2024 PR Newswire First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial
24 Jan 2024 PR Newswire Positive Xanamem® human PET study published in the Journal of Alzheimer’s Disease demonstrating robust CNS target enzyme occupancy
28 Nov 2023 PR Newswire Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
13 Oct 2023 PR Newswire Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Boston
26 Sep 2023 PR Newswire Actinogen optimizes XanaMIA Phase 2b Alzheimer’s disease trial design and provides general business update
07 Jun 2023 PR Newswire Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
05 Jun 2023 Media Insight: Beyond the amyloid hypothesis – how small molecules are giving hope to Alzheimer’s research
31 May 2023 PR Newswire Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
30 Mar 2023 PR Newswire Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference
01 Mar 2023 Biotech Daily Actinogen Appoints Nicki Vasquez Non-Executive Director
01 Feb 2023 Biotech Daily Actinogen Appoints Dr Dana Hilt CMO
22 Dec 2022 PR Newswire FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
14 Dec 2022 PR Newswire Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
25 Nov 2022 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
19 Oct 2022 Stockhead Alzheimer’s drug no longer a moonshot as race heats up, ASX-listed Actinogen in the running
11 Oct 2022 EIN Presswire Actinogen Medical (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
10 Oct 2022 Biotech Daily Actinogen Xanamem Alzheimer’s Biomarker Effect
10 Oct 2022 PR Newswire Actinogen Medical Limited (ACW) announces large Xanamem therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
14 Jun 2022 Global Newswire Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
27 Apr 2022 news.com.au Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022 The Australian Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022 Actinogen Media Release: Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s by Aussie biotech Actinogen
11 Feb 2022 The Market Herald Actinogen Medical (ASX:ACW) advances Alzheimer’s treatment
15 Jul 2021 The Market Herald Actinogen Medical (ASX:ACW) enrols first patient in Alzheimer’s Disease trial
18 Jun 2021 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
02 Jun 2021 The Market Herald Actinogen Medical (ASX:ACW) granted ethics committee approval for Alzheimers study
02 Jun 2021 Biotech Daily Actinogen: Part-A Xanamia Xanamem Cognition Trial Approved
22 Apr 2021 Biotech Daily Actinogen Plans Three Phase II Cognition Trials For 2022
15 Mar 2021 Biotech Daily Actinogen Appoints Dr Steven Gourlay CEO On $400k
11 Feb 2021 Biotech Daily Actinogen Shortfall Raises $3.55m – Total $10.9m

Latest results

2024 Half Year Financial Results

View Results Centre

2024 Annual General Meeting

Actinogen’s next Annual General Meeting

Date: November 2024 (TBA)

Read more

Back
to top